Official: Device industry won't see extra burden from Sentinel initiative

05/28/2008 | FDAnews

Device companies do not face extra regulatory requirements under the FDA's recently announced Sentinel initiative, said Thomas Gross, head of the CDRH Division of Postmarket Surveillance. He said the new program, which aims to change the agency's postmarket surveillance system, will not affect existing surveillance tools.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC